Oral hormonal contraceptive users may need additional or alternative contraception after starting tirzepatide and after dose increases, according to official labeling
16 Other less common potential adverse effects include gallbladder disease, pancreatitis and pancreatic cancer, thyroid cancer, acute kidney injury, and worsening of diabetic retinopathy (DRP)
References [edit] "Cutaneous lesions of the nose"
Gharahdaghi N, Rudrappa S, Brook MS, Idris I, Crossland H, Hamrock C, et al
This history of failures - both recent and distant - underscores the immense magnitude of our recent breakthrough, transforming it from a simple innovation into a story of scientific redemption